Table of Contents
How the Kidney Week data event ties to the CareDx investment story
CareDx (CDNA) used the American Society of Nephrology Kidney Week 2026 to spotlight fresh data on its AlloSure Kidney test, tying the product more tightly to real world transplant decision making.
The new analyses focus on donor derived cell free DNA as a signal for graft injury, especially in situations where biopsies give borderline or ambiguous results that leave clinicians uncertain about next steps.
For investors tracking CareDx, the findings matter because they speak directly to clinical utility, which is a key ingredient for long term test adoption, reimbursement durability, and potential competitive positioning in transplant monitoring.
On the market side, CareDx shares trade at US$70.49, with a 30 day share price return of 10.69% feeding into a 90 day gain of 99.07% and year to date share price return of 268.29%. The 1 year total shareholder return of 380.50% and very large 3 year total shareholder return suggest that recent momentum has sharply reshaped how investors are pricing both potential growth and risk after successive product and clinical data updates such as the Kidney Week release.
Spot 34 healthcare AI stocks that, like CareDx, sit at the crossroads of diagnostics, data and clinical decision making in transplant and organ health.
Bulls point to Kidney Week data and a 268.29% year to date surge in CareDx as evidence that the story has shifted. Bears see stretched expectations and mixed earnings trends. Which side does the valuation math lean toward next?
Most Popular Narrative: 9.9% Overvalued
Compared with the last close at $70.49, the most followed narrative pegs CareDx fair value at $64.17, implying a richer price than that framework supports and putting more weight on future execution and Kidney Week style catalysts to justify the gap.
Significant progress in payer coverage including millions of new covered lives, expanded in-network status, and the implementation of a unique CPT code for AlloSure indicates a catalyst for sustained increases in ASP (average selling price) and recurring revenue streams, which can directly enhance future profitability and margin expansion.
See why 7 investors see CareDx as 10% overvalued.
Result: Fair Value of $64.17 (OVERVALUED)
Still, shifting Medicare and LCD reimbursement policies, as well as any stumble in integrating Naveris, could quickly challenge the current CareDx growth and valuation story.
Find out about the key risks to this CareDx narrative.
